Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| MAGI'S LAB - |
RCV001787355 | SCV000844975 | likely pathogenic | Lymphatic malformation | 2018-10-25 | criteria provided, single submitter | clinical testing | The p.(Asn681Metfs*16) variant in CELSR1 has been reported in a 35-year-old female affected by lymphedema of the lower limbs as part of a syndromic picture compatible with a diagnosis of Noonan syndrome. Lymphedema of the left leg developed at 13 years of age. The proband was negative in previous genetic testing performed considering the following Noonan and Noonan-like syndrome genes: PTPN11, KRAS, SOS1, RAF1, NRAS, SHOC2. Moreover, she was tested for the Fabry disease gene GLA, and for the cardiofaciocutaneous syndrome type 3 gene MAP2K1. The frameshift variant falls in the cadherin domain of the protein causing very early termination of the protein. It can be considered a private variant since it is not listed in any of the public database questioned. The patient was tested using a custom designed next generation panel that covered the following lymphedema-associated genes: CCBE1 (OMIM 612753), CELSR1 (OMIM 604523), FAT4 (OMIM 612411), FLT4 (OMIM 136352), FOXC2 (OMIM 602402), GATA2 (OMIM 137295), GJC2 (OMIM 608803), HGF (OMIM 142409), KIF11 (OMIM 148760), SOX18 (OMIM 601618) and VEGFC (OMIM 601528). The variant was inherited from her clinically healthy mother thus showing incomplete penetrance. In summary, the p.(Asn681Metfs*16) variant meets the criteria of the American College of Medical Genetics and Genomics guidelines (Richards et al., 2015) to be classified as likely pathogenic based upon type of variation and absence from controls. |